Furthermore, in a recent retrospective study of 693 de novo AML patients with a WBC count of >50,000/μL had higher incidences of FLT3-ITD, NPM1, DNMT3A, NRAS, CEBPA, and TET2 mutations and the presence of hyperleukocytosis was independently associated with an adverse prognosis [56]. This evidence concerns the gene FLT3 and acute myeloid leukemia.